biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Bottom Line: xB3 never in a stronger position

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Dec 16, 2022 6:27pm

119 Views

Post# 35177039

RE:Bottom Line: xB3 never in a stronger position

poof, Biodexa has stated that they will not retain control of the xB3 platform.

It's not a selling point for the deal.

Why are you pumping the enemy's company, owned 75% by Ladenburg Thalmann people?

It's embarrassing. You pass yourself off as a market guru but you are driven only by your current trade and/or income source.

jd

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles